Updated April 26, 2021
Location and quantity of vaccine shipments in the county are determined by N.C. Department of Health and Human Services (NC DHHS),
not by Mecklenburg County Public Health at this time.
MCPH currently has a limited number of appointments available and will work to add additional appointment options based on vaccine supply.
If there are no appointments available, please continue to check
StarMed.care for openings or check back on this page for updates. Please reach out to
MeckCVMS@mecknc.gov with questions.
Healthcare workers may also schedule an appointment through
MyAtriumHealth, even if they are not affiliated with the hospital.
Vaccine will initially be shipped to hospitals and local health departments.
Ancillary supply kits will come with the vaccine and will include needles, syringes, alcohol prep pads, COVID-19 vaccination record cards for each vaccine recipient, and a minimal supply of personal protective equipment (PPE), including surgical masks and face shields, for vaccinators.
Identifying data includes recipients first and last name, date of birth, address, and sex.
Eligible health care providers who are interested in administering the COVID-19 vaccine and can self-register in the CVMS Provider Enrollment Portal.
Before getting started in CVMS, a representative from your organization should:
Enrollment can be initiated at http://covid.enroll.ncdhhs.gov. Enrolled COVID-19 vaccine providers must be credentialed/licensed in North Carolina.
Please understand that while currently qualified providers are welcome to enroll, requests will be addressed in an order aligned with the Prioritization Phases and the timeline for approval will vary. The state will continuously reassess enrollment prioritization based on needs.
You can find more information on enrolling in the state CVMS system by visiting:
COVID-19 Vaccine Management System (CVMS): NC DHHS COVID-19
End-to-end Provider Enrollment Process (nc.gov)
The goal of the federal government is for there to be no upfront costs to providers and no out-of-pocket cost to the vaccine recipient.
mRNA Clinical Considerations | CDCCDC Presentation (Janssen) | CDC
Pfizer BioNTech and Moderna
Janssen (Johnson & Johnson)
All currently authorized COVID-19 vaccines are not interchangeable with one another .
Safety and efficacy of a mixed series has not been evaluated.
Persons initiating series with Pfizer-BioNTech COVID-19 or Moderna vaccine should complete series with same product.
If two doses of different mRNA COVID-19 vaccine products inadvertently administered, no additional doses of either vaccine recommended at this time.
Recommendations may be updated as further information becomes available or additional vaccine types authorized.
Use of the Johnson & Johnson Vaccine to Complete an Unfinished Series
If a first dose of an mRNA COVID-19 vaccine was received but the patient was unable to complete series with the same mRNA vaccine:
Single dose of Janssen COVID-19 vaccine may be administered at minimum interval of 28 days from mRNA dose.
Considered to have received valid, single-dose Janssen vaccination, not mixed vaccination series (mRNA/viral vector).
COVID-19 vaccines should be administered alone with a minimum interval of 14 days before or after administration with any other vaccines.
Due to lack of data on safety and efficacy of the vaccine administered simultaneously with other vaccines.
If COVID-19 vaccine is inadvertently administered within 14 days of another vaccine, doses do not need to be repeated for either vaccine.
A shorter interval may be used in situations where the benefits of vaccination are deemed to outweigh the potential unknown risks (e.g., tetanus toxoid vaccine for wound management, etc.) or to avoid barriers or delays to vaccination.
Vaccination should be offered to persons regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection.
Community or outpatient setting
Residents of congregate healthcare settings (e.g., long-term care facilities)
Residents of other congregate settings (e.g., correctional facilities, homeless shelters)
All currently authorized COVID-19 vaccines may be administered to persons with underlying medical conditions who have no contraindications to vaccination.
Persons with HIV infection, other immunocompromising conditions, or who take immunosuppressive medications or therapies might be at increased risk for severe COVID-19.
There are no data on the safety of COVID-19 vaccines in pregnant women.
Clinical trials to evaluate safety and efficacy of COVID-19 vaccines in pregnant people planned or underway.
If a woman is part of a group (e.g., healthcare personnel) who is recommended to receive a COVID-19 vaccine and is pregnant, she may choose to be vaccinated. A discussion with her healthcare provider can help her make an informed decision, but is not required.
30 minute observation period if vaccinated
Differing Contraindications and Precautions Related to the Janssen (Johnson and Johnson) Vaccine
Viral tests: Prior receipt of the Pfizer-BioNTech COVID-19 vaccine will not affect the results of SARS-CoV-2 nucleic acid amplification or antigen tests.
Persons who do not meet all 3 of the above criteria should continue to follow current quarantine guidance after exposure to someone with suspected or confirmed COVID-19.
Adverse events that occur in a recipient after receipt of COVID-19 vaccine should be reported to the Vaccine Adverse Events Reporting System (VAERS).
County services are operating at a limited capacity. Questions about COVID-19? Call Public Health Hotline: 980-314-9400